Daily Respiratory Research Analysis
A high-resolution temporo-spatial atlas of the regenerating alveolar niche in idiopathic pulmonary fibrosis using imaging mass cytometry offers mechanistic insights into failed repair. Real-world registry data show that elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark pathogens in cystic fibrosis, while a prospective EEG cohort in acute hypoxemic respiratory failure identifies sedation-linked abnormal EEG patterns associated with ICU mortality.
Summary
A high-resolution temporo-spatial atlas of the regenerating alveolar niche in idiopathic pulmonary fibrosis using imaging mass cytometry offers mechanistic insights into failed repair. Real-world registry data show that elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark pathogens in cystic fibrosis, while a prospective EEG cohort in acute hypoxemic respiratory failure identifies sedation-linked abnormal EEG patterns associated with ICU mortality.
Research Themes
- Alveolar regeneration and microenvironment in pulmonary fibrosis
- Microbiological impact of CFTR modulator therapy in cystic fibrosis
- Sedation neurophysiology and outcomes in acute respiratory failure
Selected Articles
1. Temporo-spatial cellular atlas of the regenerating alveolar niche in idiopathic pulmonary fibrosis.
Using 33-plex single-cell imaging mass cytometry across human IPF tissues spanning disease stages, the authors build a temporo-spatial atlas of the regenerating alveolar niche. Unbiased mathematical analyses quantify statistically enriched cell–cell interactions, highlighting networks involving CD206-marked populations and epithelial states in regions of aberrant repair.
Impact: This work provides a reference atlas and analytical framework to interrogate failed alveolar repair in IPF, enabling hypothesis-driven target discovery for regenerative therapies.
Clinical Implications: While not immediately practice-changing, the atlas prioritizes cell–cell interactions and niches for therapeutic targeting, informing biomarker development and stratification strategies in IPF.
Key Findings
- Constructed a high-resolution, temporo-spatial cell atlas of the regenerating alveolar niche in IPF using 33-plex single-cell imaging mass cytometry on human tissues.
- Applied unbiased mathematical methods to quantify statistically enriched cell–cell interactions across disease regions.
- Highlighted interaction networks involving CD206-associated populations within areas of aberrant repair.
Methodological Strengths
- Use of 33-plex single-cell imaging mass cytometry on human IPF tissues across disease stages
- Unbiased mathematical quantification of statistically enriched cell–cell interactions
Limitations
- Observational, cross-sectional design without interventional validation
- Sample size and clinical annotation details are not specified in the abstract
Future Directions: Translate prioritized interaction hubs into functional perturbation studies and biomarkers; integrate spatial multi-omics with longitudinal sampling to link niche dynamics to patient outcomes.
Healthy alveolar repair relies on the ability of alveolar stem cells to differentiate into specialized epithelial cells for gas exchange. In chronic fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), this regenerative process is abnormal but the underlying mechanisms remain unclear. Here, using human lung tissue that represents different stages of disease and a 33-plex single-cell imaging mass cytometry (IMC), we present a high-resolution, temporo-spatial cell atlas of the regenerating alveolar niche. With unbiased mathematical methods which quantify statistically enriched interactions, CD206
2. Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry.
Across 15,739 people with cystic fibrosis from 30 countries, one year after initiating elexacaftor/tezacaftor/ivacaftor, many individuals shifted from positive to negative microbiological status for key CF-related pathogens, a shift less commonly observed before ETI. Benefits persisted into year two for early initiators, although some patients continued to harbor pathogens.
Impact: This large, multi-country real-world study quantifies microbiological benefits of CFTR triple therapy beyond lung function, informing infection monitoring and antimicrobial stewardship.
Clinical Implications: ETI therapy likely reduces airway pathogen carriage in many patients, supporting continued culture surveillance and potential de-escalation of chronic suppressive antibiotics in selected responders, while recognizing persistent carriage in some.
Key Findings
- Analyzed 15,739 people with cystic fibrosis across 30 countries initiating ETI between 2019 and 2021.
- Compared microbiological status 1 year before vs 1 year after ETI and against a pre-ETI baseline period (3 to 1 years prior) using mixed-effects models.
- Observed frequent shifts from pathogen-positive to pathogen-negative status after ETI, a change less common before ETI; benefits extended into the second year for early initiators, with some persistent carriage.
Methodological Strengths
- Large, multinational registry cohort with pre–post comparison and mixed-effects modeling
- Extended follow-up to 2 years for early initiators
Limitations
- Observational design with potential confounding and secular trends
- Pathogen-specific quantitative data and exact proportions are truncated in the abstract
Future Directions: Define pathogen- and site-specific dynamics, antibiotic stewardship algorithms post-ETI, and resistance/ecology effects using longitudinal quantitative cultures and sequencing.
BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has improved outcomes for people with cystic fibrosis (pwCF). This study evaluated changes in airway microbiological infection status after initiating ETI. METHODS: Using the European Cystic Fibrosis Society registry, pwCF who started ETI between 2019 and 2021 were identified. The changes in microbiological status from 1 year before to 1 year after ETI initiation, were compared with the changes seen from 3 to 1 years before starting ETI. Mixed-effect regression models were used to analyse changes. Data from 2 years after initiation were examined for those starting ETI in 2019-2020. RESULTS: Included were 15 739 pwCF from 30 countries. In the year before ETI, 38.4% were positive for CONCLUSION: One year after starting ETI, many pwCF who were initially positive for various CF-related pathogens, shifted to a negative status, a change less common before ETI. These findings suggest that ETI reduces airway infections, with benefits extending into the second year of treatment, although some pwCF continue to carry these pathogens despite treatment.
3. Sedation-related Electroencephalographic Patterns in Acute Hypoxemic Respiratory Failure.
In 23 mechanically ventilated AHRF patients monitored for a mean of 43 h each (1,832 h total), novel EEG patterns (EEG Ups), absent in natural sleep, occupied 42% of recording time and exceeded 50% with some sedation–opioid combinations. EEG Ups prevalence correlated with higher sedation dose, deeper clinical sedation scores, and ICU mortality.
Impact: Defines an EEG signature of continuous sedation distinct from sleep and links it to dose and outcomes, providing an objective neurophysiologic target for sedation monitoring and titration.
Clinical Implications: Continuous EEG could help distinguish sedation from physiologic sleep, guide dose titration to minimize adverse neurophysiology, and identify patients at higher mortality risk during AHRF management.
Key Findings
- EEG Ups, patterns absent in natural sleep, occupied 42% of total recording time across 1,832 h of EEG in 23 AHRF patients.
- EEG Ups prevalence exceeded 50% with certain sedation–opioid combinations and was higher with higher sedation dose and deeper clinical sedation scores (P ≤ 0.035).
- EEG Ups were associated with ICU mortality (P < 0.001), while physiologic brief wake intrusions were extremely low.
Methodological Strengths
- Prospective cohort with continuous EEG monitoring up to 7 days
- Quantitative spectral analysis across frequency bands and correlation with clinical sedation and outcomes
Limitations
- Small single-cohort sample (n=23) with potential confounding by indication and sedation regimens
- Exploratory nature limits generalizability; lacks interventional validation
Future Directions: Validate EEG Ups thresholds for risk stratification and test sedation titration protocols targeting reduction of EEG Ups in randomized trials.
BACKGROUND: There is no universal objective measure of the effect of sedation on brain activity and how to differentiate it from sleep. In patients with early acute hypoxemic respiratory failure (AHRF), the authors used the odds ratio product, an electroencephalography (EEG)-based metric used to quantify the sleep-wake continuum. Despite patients behaviorally appearing asleep, the authors observed and quantified novel EEG patterns previously unobserved during natural sleep, and hypothesized that these unnatural EEG patterns (EEG Ups ) reflect the effect of sedation. The objective of the study was to explore the relevance of EEG Ups (never or extremely rarely seen in sleep studies) and their association with sedation at the early phase of AHRF. METHODS: This was a prospective cohort study including patients mechanically ventilated for AHRF and Pa o2 /fraction of inspired oxygen less than 200 mmHg receiving various sedation-opioid regimens and doses as per clinical indication. Continuous EEG monitoring was performed from study inclusion until extubation, death, or up to 7 days. EEG quantified the relative power of each frequency band (slow delta, fast delta plus theta, alpha-sigma, beta) and determined the frequency of EEG Ups . RESULTS: A total 1,832 h of EEG recordings were analyzed (mean ± SD, 43 ± 25 h/patient) from 23 patients (median [interquartile range, 25 to 75%], 58 [48 to 70] yr; 87% male; Pa o2 /fraction of inspired oxygen, 150 [116 to 198] mmHg; intensive care unit mortality, 22%). EEG Ups accounted for 42% of the total recording time overall, differed among drug combinations, and exceeded 50% with some sedation-opioid combinations. Brief wake intrusions, a marker of physiologic sleep, were extremely low. EEG Ups prevalence was higher with sedation-opioid combinations ( P ≤ 0.029), high sedation dose ( P ≤ 0.035), and deeper clinical sedation score ( P ≤ 0.024), and was associated with intensive care unit mortality ( P < 0.001). CONCLUSIONS: Continuous intravenous sedation results in EEG Ups that are not present in natural sleep, correlate with dose of sedation, clinical sedation score, and clinical outcomes.